Kiniksa Pharmaceuticals Sponsors American Heart Association's Addressing Recurrent Pericarditis Initiative
Kiniksa Pharmaceuticals Sponsors American Heart Association's Addressing Recurrent Pericarditis Initiative
– Initiative aimed at improving access and outcomes for patients with recurrent pericarditis –
– 旨在改善複發性心包炎患者的接診和療效的倡議——
– American Heart Association to work with champions at 15 healthcare sites to implement initiative activities and improve care quality –
– 美國心臟協會與 在15個醫療保健機構的冠軍的合作下，實施倡議活動並提高護理質量——
HAMILTON, Bermuda, June 17, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today announced its sponsorship of the American Heart Association's new Addressing Recurrent Pericarditis initiative, a multi-faceted effort to improve quality of care through identification, dissemination, and implementation of best practices for the diagnosis and management of recurrent pericarditis.
百慕大，2024年6月17日（環球通訊社）--kiniksa pharmaceuticals有限公司。（納斯達克：KNSA）（Kiniksa）是一家商業化階段的生物製藥公司，擁有一系列免疫調節資產，旨在針對一系列心血管和自身免疫性疾病，今天宣佈贊助美國心臟協會的新解決複發性心包炎倡議，通過識別、傳播和實施診斷和治療複發性心包炎的最佳實踐，改善護理質量的多方面努力。
"We are proud to sponsor the American Heart Association's Addressing Recurrent Pericarditis initiative. Recurrent pericarditis is a rare, chronic, flaring disease, in which patients are frequently misdiagnosed or undertreated due to a lack of access to expert care. In addition to elevating awareness and knowledge around recurrent pericarditis, this initiative will also help strengthen overall care by working to improve processes for diagnosing, referring, and treating patients," said John F. Paolini, M.D., Ph.D., FACC, Chief Medical Officer of Kiniksa. "Furthermore, this initiative will facilitate knowledge-sharing across a collaborative network of healthcare providers, with the objective of establishing a clear model to streamline patient access to expert care and improved outcomes nationwide."
“我們很自豪地贊助美國心臟協會的解決複發性心包炎倡議。由於缺乏接受專家護理的途徑，複發性心包炎是一種罕見的、慢性的、反覆的疾病，在此類疾病中，患者經常被誤診或治療不足。除了提高人們對複發性心包炎的認識和知識，這項倡議還將通過努力改善患者的診斷、轉診和治療過程，來加強整體護理，” Kiniksa的首席醫學官John F. Paolini, M.D., Ph.D., FACC說道。“此外，這項倡議還將促進衛生保健提供者之間的知識共享，旨在建立一個明確的模式，以簡化患者接受專業護理和改善全國範圍內的效果。”
Through the Addressing Recurrent Pericarditis initiative, the American Heart Association will establish a learning collaborative of champions at fifteen healthcare sites for recurrent pericarditis care. These champions will analyze patient identification and referral pathways, seeking to identify gaps and pragmatic solutions. The ultimate goal of the initiative is to improve outcomes and quality of life for recurrent pericarditis patients by disseminating best practices through national education, model sharing, abstract development, and patient- and physician-targeted podcasts and webinars.
通過PAO行動周網站(paoactionweek.com)，患者、護理人員和一般社區可以訪問視頻，了解如何查找並參與相關PAO。有關PAO行動周的更多信息，請訪問網站並關注社交媒體上的hashtag #PAOActionWeek。解決複發性心包炎倡議，美國心臟協會將建立一個由15個醫療保健機構的冠軍組成的學習協同體，爲不斷複發性心包炎的護理提供支持。這些冠軍將分析患者識別和轉診途徑，尋求確定差距和實用解決方案。該倡議的最終目標是通過國家教育、模型共享、摘要開發以及針對患者和醫生的播客和網絡研討會等途徑，傳播最佳實踐，改善複發性心包炎患者的預後和生活質量。
"Recurrent pericarditis symptoms can have significant impact on emotional health and quality of life, but they often go undiagnosed and untreated," said Mariell Jessup, M.D., FAHA, Chief Science and Medical Officer of the American Heart Association. "This new initiative will share insights and best practices nationally to improve identification and treatment for patients with this disease."
“複發性心包炎症狀對情感健康和生活質量有重大影響，但它們經常被未被診斷和治療，”美國心臟協會的首席科學和醫療官Mariell Jessup, M.D., FAHA說道。“這項新倡議將在全國範圍內分享見解和最佳實踐，改善該疾病患者的識別和治療。”
Participating sites in the learning collaborative include:
參與學習協同體的機構包括：
- Ascension St. Thomas Heart (Nashville, Tennessee)
- Bluhm Cardiovascular Institute, Northwestern Medicine (Chicago, Illinois)
- Brigham & Women's Hospital (Boston, Massachusetts)
- Cleveland Clinic (Cleveland, Ohio)
- Houston Medical Hospital (Houston, Texas)
- Knight Cardiovascular Institute Cardiology Clinic, Oregon Health & Science University (Portland, Oregon)
- Massachusetts General Hospital (Boston, Massachusetts)
- Mayo Clinic – Rochester (Rochester, Minnesota)
- My Cardiologist/CVAUSA (Miami, Florida)
- New York University Grossman School of Medicine (New York, New York)
- Pacific Heart Institute (Santa Monica, California)
- The Regents of the University of California Irvine (Irvine, California)
- University of Michigan (Ann Arbor, Michigan)
- University of Utah Hospital (Salt Lake City, Utah)
- University of Virginia (Charlottesville, Virginia)
- 天主教聖托馬斯心臟病（田納西州納什維爾）
- 布盧姆心血管研究所，西北醫學（伊利諾伊州芝加哥）
- 布里格姆婦女醫院（馬薩諸塞州波士頓）
- 克利夫蘭診所（俄亥俄州克利夫蘭）
- 休斯頓醫學醫院（德克薩斯州休斯頓）
- 俄勒岡健康與科學大學，耐特心血管研究所心臟病診所（俄勒岡州波特蘭）
- 麻省總醫院（馬薩諸塞州波士頓）
- 梅奧診所─羅切斯特（明尼蘇達州羅切斯特）
- 我的心臟病專家/CVAUSA（佛羅里達州邁阿密）
- 紐約大學格羅斯曼醫學院（紐約，紐約州）
- 太平洋心臟研究所（加利福尼亞州聖莫妮卡）
- 加利福尼亞大學爾灣分校（加利福尼亞州爾灣）
- 密歇根大學（密歇根州安娜堡）
- 猶他大學醫院（猶他州鹽湖城）
- 弗吉尼亞大學（弗吉尼亞州夏洛茨維爾）
About Recurrent Pericarditis
Recurrent pericarditis is a painful and debilitating chronic autoinflammatory cardiovascular disease marked by inflammation of the pericardium and is often associated with changes in electrical conduction and sometimes buildup of fluid around the heart, called pericardial effusion. Recurrent pericarditis symptoms have an impact on quality of life, limit physical activities, and lead to frequent emergency department visits and hospitalizations. Data shows that approximately 40,000 patients in the U.S. seek and receive treatment for recurrent pericarditis each year. Of that group, approximately 14,000 patients experience two or more recurrences due to persistent underlying disease or inadequate response to conventional therapies, such as nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, and corticosteroids.
關於複發性心包炎
複發性心包炎是一種疼痛和令人殘疾的慢性自身免疫心血管疾病，其標誌性特徵爲心包的炎症，常伴隨着電傳導異常以及心包積液，限制了日常生活活動並導致頻繁的急診科就診和住院治療。數據顯示，美國每年有大約40,000名患者尋求並接受複發性心包炎的治療。在此群體中，約有14,000名患者因持續潛在疾病或對非甾體類抗炎藥（NSAIDs）、秋水仙鹼和皮質類固醇等傳統療法反應不佳而出現兩次或更多次的復發。
About Kiniksa
Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's immune-modulating assets, ARCALYST, abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.
ARCALYST是再生元製藥公司的註冊商標。
Kiniksa是一家商業化階段的生物製藥公司，專注於發現，收購，開發和商業化治療藥物，用於治療存在顯着未滿足醫學需求，造成患者疾病困擾的。 Kiniksa的免疫調節資產ARCALYST，abiprubart和mavrilimumab都具有強大的生物學理論或經過驗證的機制，針對一系列未得到滿足的心血管和自身免疫性疾病，並提供差異化的潛力。欲了解更多信息，請訪問www.kiniksa.com是再生元製藥公司的註冊商標。.
Forward-Looking Statements
This press release contains forward-looking statements. In some cases, you can identify forward- looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding: the ultimate number of healthcare sites that will participate in the learning collaborative; our belief that the Addressing Recurrent Pericarditis initiative will (a) improve quality of care through identification, dissemination and implementation of best practices for the diagnosis and management of recurrent pericarditis, (b) elevate awareness and knowledge around recurrent pericarditis, (c) strengthen overall care by working to improve processes for diagnosing, referring and treating patients, and (d) facilitate knowledge-sharing across a collaborative network of healthcare providers to streamline patient access to expert care and improve outcomes nationwide; that the healthcare champions participating in the Addressing Recurrent Pericarditis initiative will analyze patient identification and referral pathways, seeking to identify gaps and pragmatic solutions with the ultimate goal of improving outcomes, quality of life, identification and treatment for recurrent pericarditis patients by disseminating insights and best practices; and our belief that all of our product candidates offer the potential for differentiation.
前瞻性聲明
本新聞稿包含前瞻性聲明。在某些情況下，您可以通過諸如“可能”、“將”、“應該”、“預計”、“計劃”、“預測”、“可能”、“打算”、“目標”、“看法”、“承認”、“相信”、“估計”、“預示”、“潛力”或“繼續”等這些術語來識別前瞻性聲明，儘管並非所有前瞻性聲明都包含這些識別標誌。本新聞稿中包含的所有與歷史事實無關的聲明都應視爲前瞻性聲明，包括但不限於關於：最終會參加學習合作的醫療保健機構的數量；我們相信（轉化本應爲“認爲”）“應對複發性心包炎”努力將通過確定、傳播和實施複發性心包炎診斷和治療最佳實踐，提升複發性心包炎的認知和知識水平，通過努力改善診斷、轉診和患者治療流程，增強整體護理，並促進醫療保健提供者協作網絡的知識分享，以簡化患者接受專業護理的流程並改善全國衛生結局的預期；參加“應對複發性心包炎”工作的醫療衛勇士將分析患者識別和轉診途徑，尋求識別差距和切實解決方案，最終以傳播見解和最佳實踐的方式提高複發性心包炎患者的預後、生活質量、識別和治療水平；以及我們認爲我們所有的產品候選人都具有差異性的潛力。應對複發性心包炎這項舉措將通過確定、傳播和實施複發性心包炎診斷和治療最佳實踐（a），提升人們對複發性心包炎的認知和知識水平（b），通過努力改善患者的診斷、轉診和治療流程來增強整體護理（c），並促進醫療保健提供者之間的知識分享以簡化患者接受專業護理的流程並改善全國衛生結局的預期（d）。參加“應對複發性心包炎”工作的醫療衛勇士將分析患者識別和轉診途徑，尋求識別差距和切實解決方案，最終以傳播見解和最佳實踐的方式提高複發性心包炎患者的預後、生活質量、識別和治療水平。應對複發性心包炎我們相信參加“應對複發性心包炎”舉措的醫療衛勇士將分析患者識別和轉診途徑，尋求確定差距的解決方案，以傳播見解和最佳實踐的方式來提高複發性心包炎患者的預後、生活質量、識別和治療——以期從中受益的醫院的數量最終將是（a）和（b）的組合；我們相信所有我們的產品候選人都具有差異化的潛力。
These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our and our partners' achievements to be materially different from those expressed or implied by the forward-looking statements.
這些前瞻性聲明是基於管理層目前的預期而作出的。這些聲明既不構成承諾也不保證，但涉及到已知和未知的風險、不確定性和其他重要因素，這些因素可能會導致我們和我們夥伴的業績與前瞻性聲明中表達或暗示的業績存在實質性差異。
These and other important factors discussed in our filings with the U.S. Securities and Exchange Commission, including under the caption "Risk Factors" contained therein, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. Except as required by law, we disclaim any intention or obligation to update or revise any forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
美國證券交易委員會我們的申報中討論的這些和其他重要因素，包括其中包含的“風險因素”標題下的任何內容，可能會導致實際結果與本新聞稿中所做的前瞻性聲明所指示的結果存在實質差異。任何這樣的前瞻性聲明都代表了管理層在本新聞稿發佈之日起的估計。除法律規定外，我們聲明不承擔更新或修訂任何前瞻性聲明的任何意願或義務。這些前瞻性聲明不應視爲反映我們的觀點，也不應視爲任何日期之後的任何時候。
Every Second Counts!
每一秒都尤爲重要！
Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437
rfrank@kiniksa.com
Kiniksa投資者和媒體聯繫人
Rachel Frank
(339) 970-9437
rfrank@kiniksa.com
譯文內容由第三人軟體翻譯。